Excellent session: Navigating CV risk for #inflammatory #arthritis - view from #cardiology #ACR23 14T118 @RheumNow @ACRheum https://t.co/WKhh0TonE8

#ACR23 Late-Breaking Abstr#L14 Which team are you on? IL5-i or IL5-receptor-i #EGPA. Phase 3 H2H RCT showed similar efficacy btw Mepolizumab and Benralizumab, with more pts fully tapering off GC at WK52 favouring BENRA. Rapid reduction in Eosinophils too @RheumNow #ACRBest https://t.co/cXhSS80mA2

Is #cardiology now a specialty like #rheumatology with bDMARDs? Many pathways discussed for CVD in #rheumatoid #arthritis. And biologics for lowering lipids too! #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ 14T118. More overlap of pts over time! https://t.co/blv5GmHTGe

A#L06 #ACR23 @RheumNow Refractory juv SSc 6m-2y after autolog Stem Cell Tx - 5 patients HAQ VAS improved 75% (48-99%) All: mRSS MCID by 6 mo, 87% aver improvement, sustained at 2y GI: GIT mean 55% improvement, 1 unchanged FVC stable, DLCO improv >10% in 2, 5-10% in 2 #ACRBest https://t.co/cc6YToVEO5

#Cardiology imaging has advanced - work with #cardiologists to know what to order - esp for our Pts w #inflammatory #diseases #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ 14T118 https://t.co/RuHJuy7Dh2

Speaking of influencing in rheumatology… @RheumNow and @anisha_dua know best! #ACR23 #Facesofrheumatology https://t.co/EsppP3FPoX

MANDARA: Benralizumab v Mepolizumab in EGPA A#L14 #ACR23 @RheumNow P3, 52w RCT, 140 pts Remission rate: 59% Ben, 56.5% Mep Relapse rate 30% in both 86% Ben, 74% Mep had reduction of GC dose 50%+, 41% v 26% tapered off SAEs: 6% Ben, 13% Mep Concl: Non-inferiority of Ben v Mep https://t.co/mSIFsDq8eL

I continue to be underwhelmed by nintedanib, esp in RA-ILD Data from INBUILD-ON, f/u study to the INBUILD basket trial Persistent loss of FVC... wonder how pts would have done had they received an RA-active DMARD? Need H2H vs TNFs & real DMARDs @RheumNow #ACR23 Abstr 2158 https://t.co/56PgC6Uc67

Real-World Issues in AxSpA: Treatment Intensification, Pregnancy Dr. Rabab Nezam El-Din and colleagues explored patient- and disease-related determinants that were associated with treatment intensification among axSpA patients w/ high disease activity. https://t.co/vZ66hsErBI https://t.co/pN8JZAEcqv

• Real-World Issues in AxSpA: Treatment Intensification, Pregnancy | RheumNow

MANDARA phase 3 RCT Benralizumab vs Mepolizumab in relapsing/refractory EGPA receiving SOC. Non-inferiority met. Abstr#L14 #ACR23 @RheumNow https://t.co/UnpF3RDHMa https://t.co/076SeynJx3

Prelim data supports further evaluation of YTB323 in srSLE. #ACR23 Abs L13 reviews safety, CAR-T cell expansion, B cell depletion and initial efficacy in 1st 3 pts. https://t.co/aOLMhBBjgY @rheumnow https://t.co/2BoNeMe3Tg

Phase 2 RCT. Selective JAK1i LNK01001 in RA. 156 patients, 24 week (12 week PBO controlled). Abstr#L09 #ACR23 @RheumNow https://t.co/hHjL1yFH0H https://t.co/Qls4zRrRGH

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

The Fallacy of Biologic Treatment to Prevent RA It is time to stop fooling ourselves that we can prevent RA with our existing biologic agents. #ACR23 https://t.co/qHMW4HGkk2 https://t.co/l2Tn7hGtY3

• The Fallacy of Biologic Treatment to Prevent Rheumatoid Arthritis | RheumNow

RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? CLICK here to answer: https://t.co/tc6S3fysL3

• SPONDYLOARTHRITIS (SpA) PATIENTS (PsA, AS, and nr-axSpA) | RheumNow